GlaxoSmithKline has divested a small portfolio of OTC brands marketed in Germany and neighboring countries to chemical-free consumer health specialist PharmaSGP GmbH.
Gräfelfing, Germany-based PharmaSGP will pay around €80m ($95m) for the basket of four brands, which generated sales in excess of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?